Skip to main content
Parnax Lab Limited logo

Parnax Lab Limited — Investor Relations & Filings

Ticker · 506128 ISIN · INE383L01019 BSE.NS Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2023-11-09 Regulatory Filings
Country IN India
Listing BSE.NS 506128

About Parnax Lab Limited

https://naxparlab.com

Parnax Lab Limited specializes in the development and large-scale manufacturing of pharmaceutical formulations, with a primary focus on liquid orals, ointments, creams, and gels. The company operates advanced production facilities compliant with international quality benchmarks, including WHO-GMP standards. It functions as a contract development and manufacturing organization (CDMO), providing end-to-end solutions from formulation development to commercial production for global and domestic healthcare brands. The product range encompasses diverse therapeutic areas such as dermatology, gastrointestinal health, and pediatric care. By integrating modern technology with rigorous quality control processes, the company ensures the delivery of high-stability medicinal products. Its operations are supported by a dedicated research and development wing focused on optimizing delivery systems and enhancing product efficacy for various clinical applications.

Recent filings

Filing Released Lang Actions
Kindly find attached herewith the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 30, 2023, along with the Limited Review Report.
Regulatory Filings
2023-11-09 English
Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors of the ....
Regulatory Filings
2023-11-09 English
PARNAX LAB LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 ,inter alia, to consider and approve Standalone and Consolidated Un-audited ....
Regulatory Filings Classification · 100% confidence The document text is extremely short (96 characters) and contains only a digital signature with a date. There is no substantive content, financial data, or report information. It does not contain any report, announcement, or detailed filing. Given the lack of content, this is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other categories.
2023-11-02 English
The company has received confirmation from the RTA i.e. Link Intime India Private Limited, that there was no dematerialization received during the quarter ended September 30, 2023, therefore ....
Regulatory Filings
2023-10-10 English
Appointment of Mr. Harish S. Panpalia as a Independent Director w.e.f. 11th August, 2023
Regulatory Filings
2023-09-29 English
Closure of Trading Window w.e.f. 1st October, 2023 and shall open 48 hours after the Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2023, become generally ....
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 96 characters) and contains only a digital signature with a date and time stamp. There is no substantive content, no financial data, no report title, or any indication of the document type. It does not contain any report, announcement, or detailed information. Given the lack of content, this is likely a regulatory filing or a minimal attestation document. According to the rules, such minimal content without report data defaults to Regulatory Filings (RNS).
2023-09-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.